$OCEA News

Ocean Biomedical Intends To Develop And Operate Select Power Assets With An Initial Focus On Data Center-Grade Infrastructure And Grid-Interactive Generation; Co. Will Also Allocate A Portion Of Cash Reserves Into Bitcoin And Solana

Ocean Biomedical Intends To Develop And Operate Select Power Assets With An Initial Focus On Data Center-Grade Infrastructure And Grid-Interactive Generation; Co. Will Also Allocate A Portion Of Cash Reserves Into Bitcoin And Solana

Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China

Ocean Biomedical Receives Notice Of Grant On Patent Right From CNIPA For Its Bispecific Antibodies Targeting CHI3L1 And PD1 , Designed To Enhance T Cell-mediated Cytotoxic Effects On Tumor Cells

Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development

Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

12 Health Care Stocks Moving In Thursday's After-Market Session

Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter

Ocean Biomedical receives noncompliance letter from Nasdaq

Ocean Biomedical, Molecure sign licensing agreement for YKL-40 inhibitors

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses

Ocean Biomedical's oncology platform included in new published study

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company?s Malaria Treatment and Prevention Platforms

Ocean Biomedical: Dr. Jonathan Kurtis, MD issued patent for malaria treatment

Ocean Biomedical receives noncompliance notification from Nasdaq

Ocean Biomedical receives non-compliance notice from Nasdaq

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

12 Health Care Stocks Moving In Monday's After-Market Session